Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
China
Delay
Follow-up
Multidrug-resistant
Treatment
Tuberculosis
Journal
Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645
Informations de publication
Date de publication:
18 Jul 2020
18 Jul 2020
Historique:
received:
06
05
2020
accepted:
09
07
2020
entrez:
20
7
2020
pubmed:
20
7
2020
medline:
2
12
2020
Statut:
epublish
Résumé
China incurs an extremely low treatment coverage of multidrug-resistant tuberculosis (MDR-TB). This study aimed to understand the experience of MDR-TB patients on quality of health care, and the clinical impact through an up to six-year follow-up. Cohorts of MDR-TB patients were built in TB/MDR-TB designated hospitals in four regions of China from 2014 to 2015. Patients were followed up during treatment course, and yearly confirmation afterward until 2019. Delay in MDR-TB diagnosis and treatment was calculated upon bacteriological confirmation and treatment initiation. Risk factors for unfavourable outcomes were identified by multivariate logistic regression. Among 1168 bacteriological-positive TB patients identified from a 12-million population, 58 (5.0%) MDR-TB cases were detected. The median delay for MDR-TB diagnosis was 90.0 days, with 13.8% having a delay above 180.0 days. MDR-TB treatment was only recommended to 19 (32.8%) participants, while the rest continued with regimen for drug-susceptible TB. In MDR-TB treatment group, 36.8% achieved treatment success, while the others had incomplete treatment (21.1%), loss to follow-up (36.8%) and TB relapse (5.3%). For non-MDR-TB treatment group, 33.3% succeeded, 25.6% relapsed, 2.6% failed, 23.1% died, and 15.4% were lost to follow-up. Overall, only 35.7% (20/56) of detected MDR-TB patients had favourable outcomes and higher education level was positively associated with it (adjusted odds ratio [aOR]: 3.60, 95% confidence interval [CI]: 1.04-12.5). A large proportion of patients did not receive MDR-TB treatment and had unfavourable outcomes. Delayed MDR-TB diagnosis resulted in poor quality of MDR-TB care. Rapid diagnosis, regulated patient management and high-quality MDR-TB treatment should be enhanced in China.
Sections du résumé
BACKGROUND
BACKGROUND
China incurs an extremely low treatment coverage of multidrug-resistant tuberculosis (MDR-TB). This study aimed to understand the experience of MDR-TB patients on quality of health care, and the clinical impact through an up to six-year follow-up.
METHODS
METHODS
Cohorts of MDR-TB patients were built in TB/MDR-TB designated hospitals in four regions of China from 2014 to 2015. Patients were followed up during treatment course, and yearly confirmation afterward until 2019. Delay in MDR-TB diagnosis and treatment was calculated upon bacteriological confirmation and treatment initiation. Risk factors for unfavourable outcomes were identified by multivariate logistic regression.
RESULTS
RESULTS
Among 1168 bacteriological-positive TB patients identified from a 12-million population, 58 (5.0%) MDR-TB cases were detected. The median delay for MDR-TB diagnosis was 90.0 days, with 13.8% having a delay above 180.0 days. MDR-TB treatment was only recommended to 19 (32.8%) participants, while the rest continued with regimen for drug-susceptible TB. In MDR-TB treatment group, 36.8% achieved treatment success, while the others had incomplete treatment (21.1%), loss to follow-up (36.8%) and TB relapse (5.3%). For non-MDR-TB treatment group, 33.3% succeeded, 25.6% relapsed, 2.6% failed, 23.1% died, and 15.4% were lost to follow-up. Overall, only 35.7% (20/56) of detected MDR-TB patients had favourable outcomes and higher education level was positively associated with it (adjusted odds ratio [aOR]: 3.60, 95% confidence interval [CI]: 1.04-12.5).
CONCLUSIONS
CONCLUSIONS
A large proportion of patients did not receive MDR-TB treatment and had unfavourable outcomes. Delayed MDR-TB diagnosis resulted in poor quality of MDR-TB care. Rapid diagnosis, regulated patient management and high-quality MDR-TB treatment should be enhanced in China.
Identifiants
pubmed: 32682446
doi: 10.1186/s40249-020-00719-x
pii: 10.1186/s40249-020-00719-x
pmc: PMC7368741
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Subventions
Organisme : the Swedish Research Council and the National Natural Science Foundation of China joint project (VR-NSFC)
ID : 81361138019
Organisme : the Swedish Research Council and the National Natural Science Foundation of China joint project (VR-NSFC)
ID : 540-2013-8797
Références
PLoS One. 2016 Jan 11;11(1):e0146340
pubmed: 26751583
Lancet. 2014 Sep 13;384(9947):1005-70
pubmed: 25059949
Eur Respir J. 2006 Nov;28(5):980-5
pubmed: 16837502
Respirology. 2018 Jul;23(7):656-673
pubmed: 29641838
N Engl J Med. 2012 Jun 7;366(23):2161-70
pubmed: 22670902
Bull World Health Organ. 2015 Apr 1;93(4):279-82
pubmed: 26229192
Eur Respir J. 2012 Jul;40(1):133-42
pubmed: 22362862
BMJ Case Rep. 2018 Aug 11;2018:
pubmed: 30100573
Clin Infect Dis. 2016 Feb 15;62(4):418-430
pubmed: 26508515
Glob Health Action. 2018;11(1):1500763
pubmed: 30203719
Infect Dis Poverty. 2016 Jan 29;5:9
pubmed: 26822738
Trop Med Int Health. 2015 Nov;20(11):1431-1437
pubmed: 26171742
PLoS One. 2010 May 24;5(5):e10799
pubmed: 20520720
Clin Infect Dis. 2018 Jun 18;67(1):34-41
pubmed: 29917079
Lancet. 2007 Feb 24;369(9562):691-6
pubmed: 17321314
Lancet Infect Dis. 2018 Jun;18(6):675-683
pubmed: 29574065
Lancet Infect Dis. 2017 Mar;17(3):275-284
pubmed: 27919643
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Trop Med Int Health. 2017 Oct;22(10):1328-1333
pubmed: 28746979
Med Sci Monit. 2017 May 18;23:2348-2356
pubmed: 28520704
Trop Med Int Health. 2018 Jun;23(6):668-677
pubmed: 29691959
Infect Dis Poverty. 2016 Jan 29;5:10
pubmed: 26822583